Loading
A phase 3 trial of Ibrutinib in mantle cell lymphoma and follicular lymphoma, run by Janssen Research & Development, LLC, now recruiting.
A Long-term Extension Study of PCI-32765 (Ibrutinib) is a phase 3 interventional study registered as NCT01804686 by Janssen Research & Development, LLC, with 700 participants planned, started 2013-09-09 and due to reach its primary completion in 2026-12-31. Interventions recorded: Ibrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ibrutinib, Johnson & Johnson, Mantle cell lymphoma, Small-molecule kinase inhibitors.
Shares Ibrutinib, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Shares Ibrutinib, Johnson & Johnson, Small-molecule kinase inhibitors.
Shares Ibrutinib, Johnson & Johnson, Small-molecule kinase inhibitors.
Shares Ibrutinib, Johnson & Johnson, Small-molecule kinase inhibitors.
Shares Ibrutinib, Mantle cell lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/